相关实验视频

Updated: May 24, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

XI/XIa因子抑制剂:对抗凝血困境的潜在解决方案

Caitlin M Gibson¹, Umesh R Desai², Megan E Wesling³

¹Department of Pharmacotherapy and Outcomes Science, Virginia Commonwealth University School of Pharmacy, Richmond, VA, USA.

Expert opinion on pharmacotherapy

|March 4, 2025

概括

新型XI/XIa因子抑制剂提供了一种有希望的新方法来预防中风,通过向血栓形成而不是血液静止. 与目前的治疗方法相比,这可能会降低出血风险,尽管进一步的临床试验至关重要.

科学领域:

药理学药理学是指药理学的学科.
心血管医学心血管医学
血液学血液学血液学

背景情况:

预防中风的标准抗血栓疗法面临的局限性包括使用不足,出血风险,药物相互作用和消除.
XI/XIa因子 (FXI/XIa) 抑制剂是一种新型抗凝血剂,旨在选择性地向血栓形成,潜在地减轻出血并发症,同时保持有效性.

研究的目的:

审查FXI/XIa抑制剂背后的机制性逻辑.
描述FXI/XIa抑制分子的不同子类.
检查目前使用抗凝剂的障碍,并审查FXI/XIa抑制剂的临床试验数据.

主要方法:

机械学研究的文献综述.
对FXI/XIa抑制剂的现有临床试验数据的分析.
对FXI/XIa抑制剂与当前的抗凝固策略 (如DOACs) 的比较.

主要成果:

FXI/XIa抑制剂显示出与DOAC相比的潜在优势,包括减少出血,减少药物相互作用和减少脏排泄.
临床试验正在进行中,以证实与DOAC相比,非劣质的疗效和改善的安全性.
广泛采用的潜在障碍包括成本,缺乏特定的抗毒剂,以及抗凝剂的一般不足利用.

结论:

FXI/XIa抑制剂对改善中风预防策略具有显著的前景.
在临床试验中证明非劣质的疗效和优越的安全性对于其采用至关重要.
针对FXI/XIa的小分子和单克隆抗体的开发正在迅速推进,这表明临床转换的可能性很高.

关键词:

这是一种抗凝血药物.DOACs 是一个 DOAC.心房动是心房动的一种.一个XIa因子XIa.一次性中风中风中风中风中风

更多相关视频

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

相关概念视频

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Extrinsic and Intrinsic Pathways of Hemostasis

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...

Therapeutic Index

Therapeutic Index

The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...